Typhoid fever caused by *Salmonella enterica* serotype Typhi (hereafter referred to as *Salmonella* Typhi) remains a major health problem in the developing world ([@R1]). Treatment with appropriate antimicrobial drugs has become hampered by gradual plasmid-mediated resistance to ampicillin, chloramphenicol, and cotrimoxazole, particularly in southern and Southeast Asia ([@R2]). Consequently, since the early 1990s, fluoroquinolones (such as ofloxacin and ciprofloxacin \[Cip\]) have been widely used. However, multidrug-resistant *Salmonella* Typhi isolates that are also resistant to nalidixic acid (Nal^R^) (MIC \>256 μg/mL) and show decreased susceptibility to Cip (Cip^DS^) (MIC range, 0.125 μg/mL--1 μg/mL) have emerged and become endemic on the Indian subcontinent and in Southeast Asia ([@R3]*--*[@R5]). This resistance to quinolones was caused by amino acid substitutions in the quinolone resistance--determining region (QRDR) of the DNA gyrase subunit *gyrA*, a key target of quinolones. Because these Nal^R^--Cip^DS^ *Salmonella* Typhi strains have been associated with slower clinical responses to fluoroquinolones and treatment failures, clinical laboratories should attempt to identify these isolates ([@R3]*,*[@R6]*,*[@R7]). However, despite the accumulation of clinical, microbiologic, and pharmacokinetic--pharmacodynamic studies suggesting a resistance breakpoint of [\>]{.ul}0.125 μg/mL for ciprofloxacin, the clinical breakpoints published by the Clinical and Laboratory Standards Institute (CLSI) (susceptibility [\<]{.ul}1 μg/mL, resistance [\>]{.ul}4 μg/mL) and those from the antibiogram committee of the French Society for Microbiology (susceptibility [\<]{.ul}0.5 μg/mL, resistance [\>]{.ul}1 μg/mL) ([www.sfm.asso.fr/nouv/general.php?pa=2](http://www.sfm.asso.fr/nouv/general.php?pa=2)) have not been reevaluated ([@R6]*--*[@R9]). Use of these standard breakpoints has probably resulted in the underreporting of Cip^DS^ *Salmonella* Typhi strains. The Nal^R^ screening test has been proposed as an alternative since the mid--1990s and recommended since 2004 by CLSI and 2010 by the French Society for Microbiology ([@R3]*,*[@R7]). This screening test is based on the fact that Cip^DS^ *Salmonella* Typhi isolates with nonsynonymous (NS) mutations in codons 83 or 87 of *gyrA* are uniformly Nal^R^. However, recent reports have indicated that this approach cannot identify the newly described *Salmonella* Typhi isolates that are Nal susceptible (Nal^S^)--Cip^DS^ for which mechanisms of resistance are not linked to mutations in *gyrA* ([@R7]*,*[@R10]*,*[@R11]). Recently, NS mutations in codons 464 (Ser to Phe) and 466 (Glu to Asp) of *gyrB* were found in 7 Nal^S^--Cip^DS^ *Salmonella* Typhi isolates ([@R12]). We present data on the occurrence and characterization of the resistance mechanisms of Nal^S^--Cip^DS^ isolates in 685 *Salmonella* Typhi isolates of the French National Reference Center for *Salmonella* (FNRC-Salm).

The Study
=========

In France, laboratory surveillance of typhoid fever infections is performed by the FNRC-Salm through its network of ≈1,500 hospital and private clinical laboratories. Almost all *Salmonella* Typhi isolates in France are referred to the FNRC-Salm, and almost all are acquired abroad, mainly in Africa and Asia. Until 2009, Cip^DS^ *Salmonella* Typhi was monitored with the 30-μg Nal screening test. A total of 685 *Salmonella* Typhi isolates collected during 1997--2009 were reanalyzed to identify Nal^S^--Cip^DS^ *Salmonella* Typhi isolates. The scattergram correlating the zone diameters around the 5-μg ciprofloxacin disk with those of the 30-μg Nal disk showed 4 subpopulations, which were labeled A (554 isolates), B (11 isolates), C (119 isolates), and D (1 isolate) ([Figure 1](#F1){ref-type="fig"}). The characteristics of these populations are shown in [Table 1](#T1){ref-type="table"} and [Table 2](#T2){ref-type="table"}. The QRDRs of *gyrA*, *gyrB*, *parC,* and *parE* genes were studied on 133 isolates selected to represent diversity in terms of year of isolation, geographic origin, and MICs. To analyze the isolate characteristics, we used the following approaches: sequencing ([@R5]), denaturing high performance liquid chromatography ([@R4]), and Luminex-based genotyping assays ([@R12]). QRDR DNA sequences were compared with those of *Salmonella* Typhi strain Ty2 (GenBank accession no. AE014613). In subpopulation A, 75 isolates had wild-type QRDR sequences, whereas 2 isolates had a *gyrB* mutation at codon 465 leading to amino acid substitution Gln to Leu. Their Nal MICs were 2 and 4 μg/mL, respectively, and those of Cip were 0.04 μg/mL and 0.08 μg/mL, respectively. Notably, both isolates were acquired in Mexico during 1998 and 2009, respectively. In subpopulation C, the lowest MIC values for Cip (0.06 μg/mL) were associated with a mutation at codon 87 of the *gyrA* gene, whereas MICs did not increase with the additional mutation in the *parE* gene. Subpopulation D consisted of 1 isolate, highly resistant to ciprofloxacin, which was acquired by a traveler in India in 2004. This isolate contained 2 NS mutations in the *gyrA* gene and 1 in the *parC* gene.

![Scattergrams for 685 *Salmonella enterica* serotype Typhi isolates correlating the zone diameters around the 5-μg ciprofloxacin disk with those of the 30-μg nalidixic acid disk. Circle sizes are proportional to the number of isolates. Red lines indicate the respective antibiogram committee of the French Society for Microbiology (CA-SFM) breakpoints for ciprofloxacin (susceptible \[S\] [\>]{.ul}25; resistant \[R\] \<22 mm). Blue lines indicate the respective CA-SFM breakpoints for nalidixic acid (S [\>]{.ul}20 and R \<15 mm).](10-1242-F1){#F1}

###### Characteristics of the 674 *Salmonella enterica* serovar Typhi isolates belonging to subpopulations A, C, and D, France, 2007--2009\*

  Subpopulation   No. isolates   Nal MICs,† μg/mL             Cip MICs,† μg/mL   QRDR mutation (no./no. tested)                                 
  --------------- -------------- ------------------ --------- ------------------ -------------------------------- ------- ------- ------------- ----------------------------------------------
  MIC~50~         MIC~90~        Range              MIC~50~   MIC~90~            Range                                                          
  A               554            4                  4         1--8                                                0.008   0.025   0.002--0.08   WT (75/77)
                                                                                                                                                *gyrB* Leu465 (2/77)
  C               119            \>256              \>256     128--\>256                                          0.25    0.5     0.06--0.5     *gyrA* Phe83 (24/44)
                                                                                                                                                *gyrA* Tyr83 (12/44)
                                                                                                                                                *gyrA* Asn87 (4/44)
                                                                                                                                                *gyrA* Gly87 (2/44)
                                                                                                                                                *gyrA* Phe83 and *parE* Asn420 (2/44)
  D               1                                           \>256                                                               8             *gyrA* Phe83, *gyrA* Asn87, and *parC* Ile80

\*Nal, nalidixic acid; Cip, ciprofloxacin; QRDR, quinolone resistance--determining region of the *gyrA*, *gyrB*, *parC,* and *parE* genes; WT, wild type*.* †MICs of Nal and Cip were determined by Etest strips. MIC~50~, 50% below; MIC~90~, 90% below.

~.~

###### Characteristics of the 11 *Salmonella enterica* serovar Typhi isolates belonging to subpopulation B, France, 2007--2009

  Isolate    Year   Geographic origin   Antimicrobial drug resistance type   Disk diffusion, mm              MIC, μg/mL   *gyrB*       Haplotype       PFGE               
  ---------- ------ ------------------- ------------------------------------ -------------------- ---------- ------------ ------------ --------------- -------- --------- ----
  97-5123    1997   Unknown             Cip^DS^                              18 \[I\]             28 \[S\]                8 \[S/S\]    0.125 \[S/S\]   Tyr464   Non-H58   X8
  02-2759    2002   India               Cip^DS^                              19 \[I\]             26 \[S\]                4 \[S/S\]    0.125 \[S/S\]   Phe464   H58       X2
  05-1578    2005   India               Pansusceptible                       18 \[I\]             28 \[S\]                8 \[S/S\]    0.047 \[S/S\]   Asp466   Non-H58   X6
  05-2556    2005   India               Cip^DS^                              17 \[I\]             31 \[S\]                16 \[I/S\]   0.19 \[S/S\]    Phe464   Non-H58   X7
  05-9141    2005   India               Cip^DS^                              17 \[I\]             28 \[S\]                12 \[I/S\]   0.125 \[S/S\]   Tyr464   Non-H58   X3
  06-426     2006   India               Cip^DS^                              20 \[S\]             25 \[S\]                8 \[S/S\]    0.125 \[S/S\]   Tyr464   Non-H58   X3
  07-6086    2007   Tunisia             Pansusceptible                       16 \[I\]             31 \[S\]                16 \[I/S\]   0.047 \[S/S\]   WT       ND        ND
  08-7675†   2008   India               ASCSulTmpSXTCip^DS^                  18 \[I\]             28 \[S\]                8 \[S/S\]    0.125 \[S/S\]   Phe464   H58       X1
  09-1986†   2008   India               ASCSulTmpSXTCip^DS^                  18 \[I\]             27 \[S\]                8 \[S/S\]    0.125 \[S/S\]   Phe464   ND        X1
  09-0350    2009   Unknown             Cip^DS^                              19 \[I\]             27 \[S\]                8 \[S/S\]    0.125 \[S/S\]   Phe464   Non-H58   X5
  09-2317    2009   French Guyana       Pansusceptible                       19 \[I\]             32 \[S\]                8 \[S/S\]    0.032 \[S/S\]   Glu468   Non-H58   X4

\*PFGE, pulsed-field gel electrophoresis; Nal, nalidixic acid; Cip, ciprofloxacin; WT, wild type; ND, not determined; A, ampicillin; S, streptomycin, C, chloramphenicol; Su, sulfamethoxazole; Tmp, trimethoprim; SXT, cotrimoxazole; Cip^DS^, decreased susceptibility to ciprofloxacin. Disk diffusion test was performed and interpreted (\[S\], susceptible; \[I\], intermediate) following recommendations of antibiogram committee of the French Society for Microbiology. MICs were determined by Etest strips, and categorization was made according to the French Society for Microbiology and Clinical and Laboratory Standards Institute. †Previously described same patient ([@R13]).

Eleven isolates of subpopulation B were categorized as susceptible to Nal by determining MICs and by using CLSI breakpoints (susceptibility, [\<]{.ul}16 μg/mL; resistance, [\>]{.ul}32 μg/mL). Of the 11 isolates, 8 (from 7 patients) had a ciprofloxacin MIC [\>]{.ul}0.125 μg/mL and were thus classified as Cip^DS^ isolates. We were able to review the medical records of 2 patients infected with a Nal^S^--Cip^DS^ isolate. One patient (isolates 08-7675 and 09-1986) relapsed 15 days after completion of the treatment (oral ofloxacin, 200 mg 2×/d for 8 days) ([@R13]). The second patient (isolate 05-2556) was treated with extended-spectrum cephalosporins, and no fluoroquinolones. Regarding the resistance mechanisms the plasmid-mediated quinolone resistance--conferring genes *qnr (qnrA, B, S, D), qepA,* and *aac(6′)-Ib-cr* were not detected by PCR ([@R5]*,*[@R14]). The QRDRs of *gyrA*, *parC*, and *parE* genes were of a wild type, whereas an NS mutation was found in *gyrB* for all but 1 isolate. However, only the 8 isolates with mutations at codon 464 were Nal^S^--Cip^DS^. To assess whether these isolates were genetically related, haplotyping ([@R4]) and *Xba*I-pulsed-field gel electrophoresis (PFGE) subtyping ([@R5]) were performed. On the strength of the results, we concluded that the *gyrB* mutation was acquired independently by strains belonging to different PFGE types ([Figure 2](#F2){ref-type="fig"}). According to a newly developed single nucleotide polymorphism assay (Y.S.), 2 of these strains belong to the current emerging H58 Asian population ([@R4]), whereas the others do not ([Table 2](#T2){ref-type="table"}). In our study, the Nal^S^--Cip^DS^ isolates with *gyrB* mutations at codon 464 were most often non--multidrug-resistant and acquired mainly in India. Our first Nal^S^--Cip^DS^ isolate was isolated 13 years ago, and since is rare (prevalence ≈1%.). Although Cooke et al. ([@R10]) did not characterize isolates for their resistance mechanisms, they reported that Nal^S^--Cip^DS^ represented 11.6% (49/421) of *Salmonella* Typhi isolated in England, Scotland, and Wales during 1999--2003, while Lynch et al. ([@R11]) reported that such isolates were 4.6% (36/770) of *Salmonella* Typhi isolates identified in the United States during 1999--2006. Epidemiologic data were available for 39 isolates in the British study, 18 of which were acquired in India, 8 in Pakistan, and 4 in Bangladesh ([@R10]). The 10-fold difference in the prevalence observed between our study and that of Cooke et al. are probably related to the historical links and the subsequent population flow between the United Kingdom and the Indian subcontinent.

![*Xba*I pulsed-field gel electrophoresis (PFGE) profiles obtained from 10 *Salmonella enterica* serotype Typhi isolates belonging to subpopulation B. The dendrograms generated by BioNumerics version 3.5 software (Applied Maths, Sint-Martens-Latem, Belgium) show the results of cluster analysis on the basis of PFGE fingerprinting. Similarity analysis was performed by using the Dice coefficient, and clustering was done by using the unweighted pair-group method with arithmetic averages.](10-1242-F2){#F2}

Conclusions
===========

Nal^S^--Cip^DS^ *Salmonella* Typhi isolates originating from Asia comprise ≈1% of *Salmonella* Typhi isolates in France but are more prevalent in the United States and the United Kingdom. The NS *gyrB* mutation at codon 464 was found exclusively in Nal^S^--Cip^DS^ isolates; however, the effects of this mutation need to be formally demonstrated by site-directed mutagenesis. Furthermore, the involvement of an efflux system, such as AcrAB-TolC and OqxA, or the *qnrC* gene, have not been investigated and cannot be excluded.

Whatever the molecular mechanism of resistance of such strains, the main concern is detection of such isolates in clinical practice to prevent fluoroquinolone treatment failures. Consequently, the Nal^R^ screening test should no longer be recommended and ciprofloxacin drug MICs should be determined for all *Salmonella* Typhi isolates instead. There is also a clear need to reevaluate the clinical breakpoints for this pathogen.
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